Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2012

View Archived Issues

Amgen offers pipeline update for first quarter 2012

GSK reflects on achievements of first quarter 2012

U.K. study reveals new potential marker of acute kidney injury in acute on chronic liver failure

Promising candidate biomarker of venous thrombosis uncovered

Responses to sodium oxybate vary in phase I/II trial

FDA approves sNDA for Votrient

Afinitor approved in U.S. for new indication

Novel PLK1 inhibitor exhibits antitumor activity in vivo

Double-blind trial assesses extended-release once-daily epilepsy drug

Shionogi submits NDA for tablets to treat vulvar and vaginal atrophy

BioAlliance Pharma provides update on AMEP biotherapy

Repligen reports on RG-1068 NDA

Sanofi vaccine approved in Japan to prevent acute flaccid poliomyelitis

Orphan drug reverses vision loss in patients with Leber's hereditary optic neuropathy

Novel telomerase inhibitors developed at Pharminox

Almirall presents new SYK/JAK inhibitors

Proximagen designs novel chemokine CCR2 receptor antagonists

New monoamine reuptake inhibitors discovered in China

Kissei Pharmaceutical patents new indolizine derivatives

FDA approves new product to treat erectile dysfunction

Manhattan Pharmaceuticals to change name

Pivotal macitentan study meets primary endpoint

Athersys discusses development of cell therapy with FDA

Trimel gives update on special population study of male hypogonadism treatment

Algeta and Sanofi extend research collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...